Hypofractionated radiotherapy in prostate cancer
Mené sur 820 patients atteints d'un cancer de la prostate de stade T1b–T4 NX-0MX-0 traité entre 2007 et 2010 (âge : de 44 à 85 ans), cet essai de phase III, évalue par rapport à une radiothérapie fractionnée standard, la toxicité gastrointestinale et génito-urinaire d'une radiothérapie hypofractionnée
External beam radiotherapy is one of the standard treatment options for patients with intermediate-risk or high-risk localised prostate cancer, and more than 10 000 men are treated using this modality every year in the UK.1 Dose escalation by use of conformal radiotherapy has become a standard of care.2 Intensity modulated and image-guided contemporary radiotherapy techniques have reduced treatment-related complications3,4 and good disease control is achieved in most men with appropriate use of neoadjuvant and adjuvant androgen deprivation.
The Lancet Oncology , commentaire, 2014